Regeneron's Q3 Earnings Outperform Expectations With Dupixent Strength Balancing Eylea Weakness

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Tuesday reported third-quarter adjusted earnings of $11.83 per share, down 5% year-over-year, beating the consensus of $9.59.The company reported sales of $3.75 billion, up 1% year over year, beating the consensus of $3.59 billion.In the quarter, U.S. net sales for Eylea HD and Eylea decreased 28% year-over-year to $1.12 billion, including $431 million from Eylea HD and $681 million from Eylea.Eylea HD sales increased due to higher volumes, driven by stronger ...